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Wagner et al.' used data of Freedman et al.' 
and Shand et al.2 to construct a plot of C/ 
(AUC OT/T), which is reproduced in this ar- 
ticle as Fig. 1. The slope of the line in Fig. 1 is 
2.41, much larger than the value of unity ex- 
pected for a linear system. I was told through 
the Food and Drug Administration that this 
figure has been misunderstood by several 
people as applying universally to all first-pass 
drugs. This is an unfortunate and erroneous 
conclusion. A satisfactory explanation of the 
high correlation indicated by the figure has been 
derived and is presented below. 
Methods 
The Appendix shows the derivation of two 
new equations that give Vm and Km of the 
Michaelis-Menten equation as functions of R, 
Cli, and Cis,. These two equations (Eqs. 9 and 
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11) apply to both the venous equilibration 
model and the sinusoidal perfusion mode1,3 but 
the numerical values of Cl; , Cl, Ym, and Km 
obtained with both theories will be different 
(this will be discussed in another article). In 
Fig. 1, the ratio of ordinate/abscissa is essen- 
tially the same as the slope of the least-squares 
line forced through the origin and is equal to the 
following when Eqs. 4, 5, and 7 of the Appen- 
dix are used: 
AUC 0 T/7 
AUC 0 00/7 AUC 0 00/T 
Ds 
AUC 0 AUC 0 
= (Eq. 1) AUC 0 Dm 
AUC 0 
CI, 
CIss Vm R 
If intersubject variation of Vm is small- (i.e., 
narrow distribution), Eq. 1 indicates that all the 
points of a plot of C/ (AUC 0-00/r) would fall 
near a straight line, with a slope equal to Vm/ 
Vm -R). Table I lists the estimated values of Cli, 
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Cl, Vm, K., Cl1/C155, V./(V,,,-R), and Ess/ 
(AUC 0-00/6). Note that the numeric values of 
the last three ratios are the same for each subject 
and the averages are equal to 2.48, essentially 
the same as the slope of the least-squares line 
found through the origin in Fig. 1, namely 2.41. 
Most noteworthy in Table I is the very low in- 
tersubject variation in V., with a mean of 575 
mg/day, a coefficient of variation of 10.7%, 
and a range of 496 to 711 mg/day. It is this 
relative constancy of Vn, that causes the points 
in Fig. 1 to be grouped along a straight line with 
a relatively low degree of scatter. 
Discussion 
It is feasible with a different first-pass drug 
than verapamil that V. would vary more be- 
tween subjects and hence there would be more 
scatter in the plot of Css/(AUC 0-00/r). Hence 
one should not conclude from the nature of the 
plot for verapamil (Fig. 1) that other first-pass 
drugs give similar plots. 
Wilkinson et al.5 defined Cli as the volume of 
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Fig. 1. Plot for predicted of verapamil from 
single-dose oral data in adults. Triangles represent 
data of Freedman et al' and circles those of Shand 
et al.' Equation of line is: = 2.41X (n = 15; r = 
0.923; P < 0.001). 
water in the liver cleared of the drug per unit 
time and equal to any oral dose divided by the 
oral AUC under first-order conditions, as well 
as equal to the ratio V./Km as in Eq. 6 of the 
Appendix. Many have interpreted this to mean 
that Cl, of a given drug in a given person can 
vary widely depending on the single oral dose 
administered. I believe this is a misuse of the 
intrinsic clearance concept, and that each sub- 
ject given a certain first-pass drug has only one 
mean Cli, which may exhibit some intrasubject 
variation in estimation from time to time. How- 
ever, if there is a trend such that estimated 
clearance decreases with increase in dose or R, 
then the highest clearance corresponding to the 
lowest dose or R most closely approaches the 
actual Cli. If several different Dss have been 
given or several different Rs have been studied 
at steady state, the best estimate of Cli would be 
obtained by plotting the estimated clearance 
against Ds or R, fitting a straight line to the data 
with the use of the intercept of the line on the 
ordinate as the estimate of Cli. This follows 
from Eq. 5 of the Appendix, which indicates 
that a plot of C15/R will be a straight line with 
an intercept of V./Kn, and a slope equal to 
Abbreviations used 
AUC 0 T: AUC during 7 at steady state 
AUC 0 oc: AUC from zero to infinity after 
D, 
Cli: Intrinsic clearance of drug, equal 
to Vm/Km and estimated from 
Ds/AUC 0-00 after a low D, 
Clss: Clearance of drug at steady-state, 
corresponding to R 
C: Steady-state plasma 
concentration after oral 
administration at a constant R 
C: Average steady-state plasma 
concentration after intermittent 
oral therapy when Dm 
given every T hours 
Dm: Maintenance dose of the drug 
administered orally 
Ds: Single dose of drug 
Km: Michaelis constant 
r: Correlation coefficient for 
regression of Y on X 
R: Dosing rate, equal to Din/7 
Dosing interval 
Vn,: Maximal velocity of metabolism 
v: Instantaneous rate of metabolism 
at time t, corresponding to C 
or C 
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Table I. Parameter values for verapamil estimated from single-dose and steady-state plasma 
concentrations 
-1/Km. As indicated by Eq. 6 of the Appendix, 
Cl, is the limit of Cl as R approaches 0. 
First-order kinetics assume that R or 135 are 
small enough that differences in these values 
will yield essentially the same value of Cli. In 
the estimation of the verapamil parameter val- 
ues in Table I, it has been assumed that the Cli 
estimated from a single 80-mg dose of Freed- 
man et al.' and the first 120-mg dose of Shand 
et al.2 is the actual Cli. If these clearances are 
less than the true Cli, then the reported Km and 
Vm are higher than the true values, as can be 
seen from Eqs. 9 and 11 of the Appendix. 
I believe that essentially all drugs that exert a 
significant first-pass effect will exhibit non- 
linear Michaelis-Menten kinetics after oral ad- 
ministration at an R in the therapeutic range, as 
a result of the high drug concentrations entering 
the liver with this route compared with those 
after intravenous administration. Support for 
this statement will be published. 
Appendix 
When Michaelis-Menten elimination kinetics and 
the mammillary model with central compartment 
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*AUC values of Shand et al.' were adjusted from the actual dosage interval of 8 hr to those expected for a 6-hr dosage interval (as explained 
in original article). 
tR was 320 mg/day, or 80 mg every 6 hr. 
*It was 360 mg/day, or 120 mg every 8 hr. 
elimination apply, then v at steady-state is equal to R 
according to Eq. 2: 
v = R = Vm C" 
Km + Css 
Rearrangement of Eq. 2 gives Eq. 3: 
R 
Css 
- R ( Vm - R \ 
Km / 
and Eq. 4 follows: 
(4) 
By comparing the denominators of Eqs. 3 and 4, we 
see that: 
- R Dm Cls, = 
Km AUC 0 - 7 
Also, for a low Ds: 
Ds lim Cli = = - 
Km AUC 0 - oo Cls, (6) 
From Eqs. 5 and 6 we obtain Eq. 7: 
(5) 
Reference for 
data source 
Subject 
No. 
Cli 
(Ilmin) 
Cl. 
(Ilmin) 
Vm 
(mg/day) (nglml) Cli/C1 
Vm1 
(Vm - R) 
C1 
(AUC 0 - 0016)* 11-1 2.640 1.195 585 154 2.21 2.21 2.21 
2 4.474 1.669 510 79.2 2.68 2.68 2.68 
3 3.663 1.468 533 101 2.49 2.50 2.49 
4 7.286 2.589 496 47.3 2.82 2.82 2.81 
5 2.597 1.179 586 157 2.20 2.20 2.21 
6 4.415 1.612 505 79.3 2.74 2.73 2.74 
7 2.545 1.199 605 165 2.12 2.12 2.12 
8 2.465 1.031 547 154 2.39 2.41 2.39 
9 7.366 3.777 657 61.9 1.95 1.95 1.95 
1 3.236 1.343 615 132 2.41 2.41 2.40 
2 2.457 1.027 619 175 2.39 2.39 2.39 
3 2.041 1.006 711 242 2.03 2.03 2.03 
4 1.810 0.723 599 230 2.51 2.51 2.50 
5 2.869 0.955 541 131 3.00 2.99 3.01 
6 3.891 1.170 515 91.9 3.32 3.32 3.33 
3.583 1.463 575 133 2.48 2.48 2.48 
CV (%) 47.9 52.9 10.7 43.3 15.2 15.1 15.2 
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V, R 
CL, Vn, R 
= 1 
Cl; n, Vm V (7) 
Km 
Rearrangement of Eq. 7 yields Eqs. 8 and 9: 
CI, _Vm 
Cl V, R 
V, (C188/C1i) 
From Eqs. 5 and 6 we obtain Eq. 10: 
V. (V. R) R 
CI, 
' 
(10) 
Km 
Rearrangement of Eq. 10 gives Eq. 11: 
Km = 
Cli CIss 
For intermittent oral or intravenous dosing, R be- 
comes Dm/T and C becomes C = AUC 0 T/T. If 
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unchanged drug is excreted in the urine according to 
first-order kinetics, R in the above equation must be 
adjusted for urinary excretion of unchanged drug. If 
there are "i" metabolites formed in parallel paths, 
then Vm/Kn, is replaced by /Vnil/Knn. 
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